|
|
작성일 : 22-06-06 00:54
|
글쓴이 :
Beulah (196.♡.20.86)
 조회 : 3,336
|
BRITISH CANNABIS is the leading private CBD supplier in the UK. A total of 310 products that are associated with British Cannabis were recently advanced to regulators. An analysis of the list released by the Food Standards Agency earlier this month shows.
The Berkshire-based company was approved for 75 products it submitted alone and 235 that it submitted in collaboration with other companies. As reported by the List, which was released on March 31, 3,536 products were certified by FSA preliminarily as "novel" or new foods.
RX Pharmatech Ltd. in Bradford, West Yorkshire, has seen 273 products it is associated with approved. This is the second-highest number RX Pharmatech submitted 11 products by itself and 157 with other producers.
According to the Association for the Cannabinoid Industry. (ACI), the UK market for CBD products was worth PS690million. According to ACI, CBD sales in the UK more than doubled between 2019 and 2021, this makes the UK the second-largest consumer market outside of the USA.
Companies remaining
374 companies were able to see products promoted by the FSA. Some companies applied separately; others were only participants in joint applications filed with other producers. Other companies also filed independent applications. Other companies also filed independent applications. These products were included in 70 CBD application submitted to FSA.
Products that were on the list may still be available for sale. However, products that did not pass FSA scrutiny must be removed from market. FSA stresses that the approvals were preliminary and that certain products could be removed at later stages.
Many of these products were promoted to pre-validation status ("awaiting proof"), the second phase of FSA's novel product approval process. Fifty-seven of the products are now in the last stage and await FSA’s final decision.
Clearance is what you seek
FSA's novel foods approval process is designed to clarify a growing gray market, which has seen thousands of CBD products appear in retail outlets over recent years. FSA guidelines stipulate those products in distribution must have been available before February 13, 2020. All products that were introduced after this date are not eligible for consideration.
According to the Association's website, British Cannabis products were likely obtained through a consortium that was organized by the ACI. ACI said this week that it is still analyzing FSA lists and refused to reveal information about the total number of products it received through its consortium, or the names of the companies involved in the submissions (FPs). ACI has at least 628 products that were developed by members, including British Cannabis.
Applications of EIHA
RX Pharmatech submitted its products to the European Industrial Hemp Association (EIHA), which saw 1,992 CBD products be preliminarily accepted, representing roughly 56%.
EIHA Projects GmbH submitted products from 193 companies. The EIHA saw 1,992 CBD products preliminarily approve, accounting for about 56%.. The applications covered both full-spectrum extracts (835) and isolates (1,157).
A quick look at the top companies
There were 374 companies involved in the entire list of 3,536 products, here are five top-five based on the number approved by FSA.
British Cannabis
British Cannabis was established in 2015. It is an independent, vertically integrated producer and distributor of cannabis, CBD, and other cannabinoid-rich products.British Cannabis supplies white-label products to other brands and makes its own brand products. BRITISH CANNABIS operates its own laboratory, manufacturing facility and warehouse, the company also has dispatch operations and a farm for cannabis research in Portugal. The company claims that it has shipped more than 50k bottles of CBD oils between its two largest white label clients. BRITISH CANNABIS announced in September 2021 it was planning to invest in a new facility. The facility will have an ISO-accredited lab (British Cannabis Analytics), as well as a cosmetics line. This could increase its potential capacity by up to three times. It owns one of the 35 UK "chemist Ring Trial" testing labs for measuring CBD and cannabinoid in commercial products.
Associated principals : Thomas Whettem CEO & Founder, David Ralston, Managing director
RX Pharmatech Ltd
RX Pharmatech Ltd. has very little information available, it apparently doesn't have a website. Other sources indicate that the company started in May 2016. RX Pharmatech sells bulk isolates from and distillates that are produced by GVB Biopharma (Las Vegas, Nevada), USA. RX Pharmatech is a party to the FSA's second-highest product list. GVB, Las Vegas, Nevada, USA, claimed in a Press Release April 7, 2020 that it is also the largest supplier to producers of white-label formulations for oral vape liquids. GVB stated it sources raw material from a U.S. farmers' cooperative. GVB's website states that the company has a UK branch in Doncaster (Yorkshire, England). GVB's website indicates that there is a UK office located in Doncaster, Yorkshire. GVB only has one investor, Decathlon Capital Partners. GVB claims that it has operations in Europe (unidentified location) and Bogota, Colombia. GVB Biopharma joined Medicaleaf Ltd. and Cheltenham, Gloucestershire as part of its partnership with RX Pharmatech to submit three products to the FSA. GVB Biopharma, is being reported to be under a strategic alliance with Sonder Fulfillment. Sonder Fulfillment a division Golden Triangle Ventures, a Las Vegas-based pennystock company.
Principals associated with RX Pharmatech Ltd. Dominic James Bartle is the director and Damien Jonathan Bove is the director. GVB Biopharma Phillip Swindells is the CEO and co-founder. Jack Feldman is president & Co-founder. Hugh Kinsman is CFO.
Mile High Labs
Mile High Labs in Broomfield, Colorado is a supplier for CBD, CBN and CBG. Mile High reported that in 2019, it raised $100 million through two rounds of funding, including $65 million from MGG Investment Group, New York (2019). Mile High uses raw materials sourced from the USA's contracted CBD hemp growers to create an extraction facility. According to the company website, it also has a Belfast office.
Associated principals Jonathan Hilley CEO, Ryan Keeler COO, Jodi Gatica VP Quality, Danny Moses, Investor.
Taylor Mammon Ltd
Taylor Mammon Ltd. describes itself as a white label manufacturer and cannabidol distributor, based in Welwyn Garden City. The company is owned by Kentucky-based parent GenCanna. Also known as OGGUSA Inc., GenCanna was famously bankrupted in 2020. In May 2020, GenCanna's majority of assets were sold to MGG Investment Group in New York. This private lender was also one of GenCanna’s creditors. GenCanna acquired Taylor Mammon and UK's cbd oil Capital last year.
Associated principals : Taylor Mammon - Alex Taylor, cofounder; James Taylor chief commercial officer; Nathan Wogman cofounder and managing director. GenCanna/OGGUSA Inc. - Andrew Barnett, CEO; Hassan Akhtar, managing director, Europe.
Sativa Wellness Group
The company, now known as Goodbody Health Inc., has submitted its novel food applications under Sativa Wellness. The Canada-based company is an OTC trader of around 20 CBD products. These include oils, capsules, gummies and cosmetics. There are also laboratories in the UK and Poland for testing CBD products.Goodbody/Sativa Wellness headquarters is located in Vancouver (British Columbia), with an office in Beckington, Somerset. In 2020, when public financial records are available, the company posted a loss in excess of $6.5million (PS5 million). Goodbody shares trade at $0.05 (5c) currently. Goodbody's UK-based subsidiary, PhytoVista Laboratories was granted a controlled drug license in April 2022.
Associated principals (Goodbody Health Inc.): Geremy Tom, Founder & Executive Chair; Marc Howells CEO; Anne Tew CFO and Corporate Secretary.
|
|
|
